Partnerships
January 21, 2013
Our partnership strategy, particularly in biotechnologies and biotherapy, forges strategic collaborations with recognised experts around the world to achieve faster, better progress towards new therapeutic solutions.
Innovation begins with creative curiosity, an open mind and a spirit of collaboration: future successes in medicine, where team spirit has always been vital, will come from building on shared ideas.
At every level, Sanofi is committed to turning external scientific breakthroughs into successful innovative products. As a global enterprise, we seek out public and private partnerships that will open doors to new solutions for better health and we are determined to remain at the cutting edge in the field of biotherapy, stem cells and regenerative medicine, as well as expanding our portfolio with services or technologies beyond our current key areas of research. In 2011 we expanded our growth through 30 new acquisitions and partnerships and we now have products in areas our own internal programmes have not yet explored:
We have been working with Regeneron to develop and commercialise human therapeutic antibodies, and in August 2012 Sanofi and Regeneron will share promotion rights to Zaltrap which was approved by the FDA
Our acquisition of the French biopharmaceutical company Fovea gives Sanofi a unique technology platform and several discovery programmes dedicated to diseases of the back of the eye, including investigating Ecallantide for treating retinal vein occlusion induced macular edema
In vaccines, Sanofi Pasteur MSD recently partnered with the Dutch firm Crucell to develop a new generation of monoclonal antibodies to fight rabies
In the UK, we have invested in external R&D and clinical trials, and partner a strong and diverse range of universities and related institutions with established technology transfer groups. These include partnering the Juvenile Diabetes Research Foundation in the area of autoimmunity and beta cell regeneration and collaborating with Oxford BioMedica to develop novel gene-based medicines.
With ongoing demands for vaccines, Sanofi Pasteur MSD has developed partnership opportunities to boost its development and production capabilities for both prophylactic and therapeutic human vaccines. Key focus is on global solutions for multi drug-resistant infections in hospitals and nursing homes and solutions for neglected diseases in developing countries.
